Arrowhead Pharma receives Investment Bank Analyst Rating Update
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) reported Q3 EPS of ($0.68), $0.11 worse than the analyst estimate of ($0.57). Revenue for the quarter came in at $32.41 million versus...
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) reported Q2 EPS of $0.41, $0.44 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $151.81 million versus...
Equal-weight ETFs invest equally between all holdings Inherently value-based Can mitigate risk as diversifies based on value Wall Street is enjoying a positive week, thanks to...
Stocks on Wall Street ended the week on a high note, with indexes looking past inflation worries as most major averages closing within sight of their recent records. The NASDAQ...
Wall Street is sending mixed signals. While the S&P 500 is up 45% from its March lows, the market was choppy throughout most of June and July. On top of this, new COVID-19...
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company uses a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's pipeline includes ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-HSD for liver disease, ARO-ENaC for cystic fibrosis, ARO-HIF2 for renal cell carcinoma, ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-LUNG2 for chronic obstructive pulmonary disorder, and ARO-COV for the coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens.
|Average||74.08 (+120.67% Upside)|
|No. of Analysts||12|